Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$7,208 Mln
P/E Ratio
--
P/B Ratio
3.18
Industry P/E
--
Debt to Equity
0.06
ROE
-0.29 %
ROCE
-27.81 %
Div. Yield
0 %
Book Value
13.48
EPS
-3.57
CFO
$-895.77 Mln
EBITDA
$-1,140.87 Mln
Net Profit
$-1,093.58 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Revolution Medicines (RVMD)
| -11.36 | -1.45 | -5.42 | 8.94 | 21.93 | 7.74 | -- |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Revolution Medicines (RVMD)
| 51.99 | 20.40 | -5.36 | -36.42 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.00 | 0.01 | -- | -- | |
| 0.03 | 0.09 | -- | -147.67 | |
| 1.89 | 20.33 | -- | -240.85 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as... monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Read more
CEO, President & Chairman
Dr. Mark A. Goldsmith Ph.D.
CEO, President & Chairman
Dr. Mark A. Goldsmith Ph.D.
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Revolution Medicines Inc (RVMD) stood at $ 2,558 Mln as on 31-Dec-24
The share price of Revolution Medicines Inc (RVMD) is $38.77 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Revolution Medicines Inc (RVMD) has given a return of 21.93% in the last 3 years.
Revolution Medicines Inc (RVMD) has a market capitalisation of $ 7,208 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Revolution Medicines Inc (RVMD) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Revolution Medicines Inc (RVMD) and enter the required number of quantities and click on buy to purchase the shares of Revolution Medicines Inc (RVMD).
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
The CEO & director of Dr. Mark A. Goldsmith Ph.D.. is Revolution Medicines Inc (RVMD), and CFO & Sr. VP is Dr. Mark A. Goldsmith Ph.D..
There is no promoter pledging in Revolution Medicines Inc (RVMD).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
2
|
|
|
0
|
|
|
0
|
|
|
2
|
| Revolution Medicines Inc. (RVMD) | Ratios |
|---|---|
|
Return on equity(%)
|
-29.33
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Revolution Medicines Inc (RVMD) was $0 Mln.
$0.19
(
